A Multicenter, Double-blind, Placebo Randomized , Phase2b Study to Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH).

Haisco Pharmaceutical Group Co., Ltd.1 site in 1 country186 target enrollmentJanuary 5, 2024

ConditionsNon-Alcoholic Steatohepatitis (NASH)

InterventionsHSK31679 80mg HSK31679 160mg Placebo

DrugsHSK31679 80mg HSK31679 160mg Placebo

Overview

Phase: Phase 2
Intervention: HSK31679 80mg
Conditions: Non-Alcoholic Steatohepatitis (NASH)
Sponsor: Haisco Pharmaceutical Group Co., Ltd.
Enrollment: 186
Locations: 1
Primary Endpoint: Proportions of patients(HSK31679-treated versus placebo-treated) with NASH improvement and with no worsening of fibrosis at week 52 compared with Baseline.
Status: Completed
Last Updated: 2 months ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

A double-blind placebo controlled, randomized, Phase 2b study to evaluate the efficacy and safety of once-daily, oral administration of 80 or 160 mg HSK31679 versus matching placebo in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis.

Registry

clinicaltrials.gov

Start Date

January 5, 2024

End Date

January 16, 2026

Last Updated

2 months ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Haisco Pharmaceutical Group Co., Ltd.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Must be willing to participate in the study and provide written informed consent.
•Male or female aged 18 ≤ age \< 65 at the time of signing the informed consent
•Must have had prior liver biopsy within 180 days of randomization with fibrosis stage 2 to 3 and a NAS of ≥4 with at least a score of 1 in each of the lobular inflammation and ballooning degeneration.
•Must have confirmation of ≥8% liver fat content on MRI-PDFF.
•Weight changes≤5% in the 6 weeks prior to randomization.If a historical biopsy is to be used, patients must have had weight changed≤5%, too.

Exclusion Criteria

•History or presence of cirrhosis，hepatic decompensation or impairment defined as presence of any of the following: history of esophageal varices, ascites, or hepatic encephalopathy, or hepatocellular carcinoma.
•Use of high dose vitamin E (\>400 IU/day)，polyunsaturated fatty acid or ursodeoxycholic acid unless stable for ≥6 months prior to an eligible screening liver biopsy. Use of thiazolidinediones, sodium-glucose co-transporter 2 inhibitors or a complex oral anti-diabetic (OAD) regimen (3 or more OADs) unless stable for ≥3 months prior to an eligible screening liver biopsy.
•Use of Glucagon-like peptide 1 \[GLP-1\] agonist therapy (e.g.,liraglutide, semaglutide, dulaglutide and exenatide ) within 6 months prior to an eligible screening liver biopsy.
•Use of drugs that have the potential to affect thyroid hormone production and/or interfere with thyroid function.
•Potent inhibitors of CYP2C8 such as gemfibrozil and trimethoprim are prohibited. An inducer of CYP2C8, rifampicin, is prohibited.
•Use of drugs historically associated with NAFLD/NASH for 2 weeks prior to an eligible screening liver biopsy, which include, but are not limited, to the following: total parenteral nutritionamiodarone, methotrexate, systemic glucocorticoids (if use within 3 months prior to a biopsy is also not permitted), tamoxifen, tetracycline, estrogens at doses greater than those used for hormone replacement or contraception, anabolic steroids , valproic acid, and known hepatotoxins.
•Regular use of drugs historically associated with NAFLD/NASH within 12 months prior to liver biopsy (including historical biopsy), which include, but are not limited, to the following:PPAR agonists (e.g. lanifibranor, Siglitazone sodium) ，FXR agonists (e.g., obecholic acid, HTD1801)，FGF21 analogs (e.g., AP025, efruxifermin , pegozafermin(B1089-1001)) ; DGAT2 inhibitors (e.g., PF 6865571 and ION224),PDE inhibitors (e.g., ZSP1601) and other thyroid hormone receptor B agonists \[e.g.,resmetirom（MGL-3196）、ASC41 and VK2809).
•Lipid-lowering therapy that did not meet the following criteria: fenofibrate, ezetimibe stable for at least 3 months before randomization and remained unchanged during study treatment, and statins stable for at least 4 weeks before randomization and remained unchanged during study treatment.
•Type 1 diabetes or uncontrolled Type 2 diabetes defined as:
•Hemoglobin A1c \>9.5% at screening (patients with HbA1c \>9.5% may be rescreened),

Arms & Interventions

Double-blind 80 mg Daily

Patients take double-blind HSK31679 80 mg for 52 weeks

Intervention: HSK31679 80mg

Double-blind 160 mg Daily

Patients take double-blind HSK31679 160 mg for 52 weeks

Intervention: HSK31679 160mg

Placebo

Patients take double-blind placebo for 52 weeks

Intervention: Placebo

Outcomes

Primary Outcomes

Proportions of patients(HSK31679-treated versus placebo-treated) with NASH improvement and with no worsening of fibrosis at week 52 compared with Baseline.

Time Frame: from Baseline to 52 weeks

Improvement of NASH is defined as a 2-point reduction in NAS with at least 1-point reduction in ballooning and no increase in steatosis.

Secondary Outcomes

Proportions of patients(HSK31679-treated versus placebo-treated) with improvement in liver fibrosis greater than or equal to one stage and no worsening of NASH at week 52 compared with Baseline.(from Baseline to 52 weeks)
Proportions of patients(HSK31679-treated versus placebo-treated) with both improvement of NASH and fibrosis at week 52 compared with Baseline.(from Baseline to 52 weeks)
The percent relative change from baseline in hepatic fat fraction by MRI-PDFF at 12, 24, 36 and 52 weeks for HSK31679 versus placebo.(from Baseline to 12, 24, 36, and 52 weeks)
The proportions of patients with 30% or more relative hepatic fat reduction at 12 , 24 , 36 and 52 weeks for HSK31679 versus placebo.(from Baseline to 12, 24, 36, and 52 weeks)
Assess the effect of HSK31679 compared to placebo on Parameters of blood lipids measured by percent change from Baseline to 12, 24, 36, and 52 weeks.(from Baseline to 12, 24, 36, and 52 weeks)